Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16983| Title: | Theranostics of Neuroendocrine Tumors | Austin Authors: | Lee, ST;Kulkarni, HR;Singh, A;Baum, RP | Affiliation: | Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany |
Issue Date: | Oct-2017 | Publication information: | Visceral Medicine 2017; 33(5): 358-366 | Abstract: | Somatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/16983 | DOI: | 10.1159/000480383 | Journal: | Visceral Medicine | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/29177165 | Type: | Journal Article | Subjects: | Diagnosis Neuroendocrine tumor, NET Peptide receptor radionuclide therapy, PRRT Positron emission tomography/computed tomography, PET/CT Theranostics |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.